TICKERNERD
Menu
CNTNHealthcare · Biotechnology

CNTN Stock Forecast: Canton Strategic Holdings, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$2.19

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$174.5M
Ticker Nerd rank
12 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$36.9M
Net income−$47.3M
Free cash flow−$62.5M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

CNTN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Canton Strategic Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
70
Momentum
59
Quality
42
Volatility
40
Growth
30
Revisions
25
Issuance
24
Accruals
9
Value
5

Size (70): Smaller than most of the companies we track.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNTN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTN, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNTN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CNTN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Canton Strategic Holdings, Inc. (CNTN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 85% of US stocks

Price / sales
116.7×

Cheaper than 4% of US stocks

Price / book
0.4×

Cheaper than 87% of US stocks

EV / EBITDA
−6.8×

Cheaper than 81% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
−80.4%

Higher than 14% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−42.2%

Higher than 23% of US stocks

Return on assets
−11.7%

Higher than 25% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Canton Strategic Holdings, Inc. (CNTN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Canton Strategic Holdings, Inc. has a market value of $174.5M and an enterprise value of $137.3M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$80.7M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$153.5M.

  • Shares outstanding: 56.7M.

  • Trailing P/E: −2.0×.

  • Canton Strategic Holdings, Inc. employs 12 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 24 Aug 2026

Data provided by Twelve Data

Peers

CNTN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTNCanton Strategic Holdings, Inc.$174.5M
12
MDWDMediWound Ltd.$169.4M
29
INDPIndaptus Therapeutics, Inc.$171.9M
24
HUMAHumacyte, Inc.$173.2M
18
CUECue Biopharma, Inc.$174.2M
47
MENSJyong Biotech Ltd.$161.8M
3
CRBUCaribou Biosciences, Inc.$178.0M
57

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Canton Strategic Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNTN news & analysis

Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results

PRNewsWire · 14 Aug 2026positive

Canton Strategic Holdings reported its financial and operating results for the second quarter ended June 30, 2026, recording its first operating revenue from locking service and Super Validator operations while completing the sale of its legacy biotechnology subsidiary Gravitas. The announcement was made via press release on August 14, 2026.

Why it matters — This marks the company's first meaningful operating revenue from its core Canton Coin-related operations and completes its exit from the biotechnology business, reflecting a shift toward its digital asset strategy.

Canton Strategic: Highly Intriguing Blockchain Treasury With Tangible Risks

Seeking Alpha · 6 Aug 2026neutral

Canton Strategic Holdings, Inc. has pivoted from biotech into a pure-play blockchain treasury centered on Canton Coin and Super Validator operations, targeting institutional adoption and privacy-focused blockchain solutions. Despite operational progress and some institutional backing, CNTN remains pre-revenue, loss-making, and exposed to regulatory, custodial, and adoption risks.

Why it matters — A CNTN watcher would care because the company's full pivot into a blockchain treasury model documents both its strategic repositioning and the unresolved risks that will shape its viability.

Three New Directors Elected to the Board of Canton Strategic Holdings, Inc.

PRNewsWire · 28 July 2026positive

Canton Strategic Holdings, Inc. announced that Sean Galvin, Pamela L. Carter, and Rishi Nangalia were elected as directors to its Board of Directors, effective July 13, 2026, following the Company's Annual Shareholder Meeting.

Why it matters — A CNTN watcher would care because the appointments are described as strengthening governance as the Company advances its Canton Network strategy.

FAQ

Frequently asked questions about CNTN stock

How does Ticker Nerd's model rank CNTN?

As at 22 Aug 2026, Canton Strategic Holdings, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (70 of 100).

What is the CNTN stock forecast for 2030?

No analyst covering Canton Strategic Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTN are extrapolating price history, which says nothing about the business.

What does Canton Strategic Holdings, Inc. do?

Canton Strategic Holdings, Inc. is a publicly traded company focused on leveraging Canton Coin to support the Canton Network, the first privacy-enabled public blockchain processing $9 trillion in monthly transaction volume.

What is the latest news on CNTN?

The most recent item we track (PRNewsWire, 14 Aug 2026): "Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results". Canton Strategic Holdings reported its financial and operating results for the second quarter ended June 30, 2026, recording its first operating revenue from locking service and Super Validator operations while completing the sale of its legacy biotechnology subsidiary Gravitas. The announcement was made via press release on August 14, 2026.

Company

About Canton Strategic Holdings, Inc.

Canton Strategic Holdings, Inc. is a publicly traded company focused on leveraging Canton Coin to support the Canton Network, the first privacy-enabled public blockchain processing $9 trillion in monthly transaction volume. Formerly Tharimmune, Inc., it rebranded effective February 18, 2026, aligning with its digital asset treasury strategy initiated through a $545 million private placement in November 2025. The company drives value via Canton Coin acquisition, operation of a Super Validator on the network, and investments in applications that promote institutional utility and adoption across capital markets. It remains the first and only publicly traded entity backed by the Canton Foundation, featuring institutional expertise on its board, including former CFTC Commissioner Jill Sommers. Additionally, Canton Strategic Holdings maintains clinical-stage biotech research and development in inflammation and immunology. Key milestones include a $55 million registered offering for expansion and quarterly ecosystem reporting commitments. Positioned at the forefront of digitizing traditional financial markets, it facilitates onchain innovations like tokenized U.S. Treasury securities and enterprise payroll solutions.

CEO Mr. Mark Wendland · 12 employees · United States · https://www.cantonstrategic.com